Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM57SVW)

Drug Name
benzamil Drug Info
Synonyms
Benzamil; 2898-76-2; UNII-04659UUJ94; N-(N-Benzylamidino)-3,5-diamino-6-chloropyrazine carboxamide; GNF-Pf-192; CHEMBL212579; CHEBI:34558; 04659UUJ94; 3,5-Diamino-6-chloro-N-(imino((phenylmethyl)amino)methyl)pyrazinecarboxamide; 3,5-diamino-N-(N'-benzylcarbamimidoyl)-6-chloropyrazine-2-carboxamide; Pyrazinecarboxamide, 3,5-diamino-6-chloro-N-(imino((phenylmethyl)amino)methyl)-; Spectrum3_001823; Prestwick1_000657; Prestwick3_000657; Prestwick2_000657; Prestwick0_000657; Lopac-B-2417; AC1L33CQ; Lopac0_000211; KBioGR_000300
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
108107
ChEBI ID
CHEBI:34558
CAS Number
CAS 2898-76-2
TTD Drug ID
DM57SVW
VARIDT Drug ID
DR01348

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DOT
Drug Status:
Investigative Drug(s)
Approved Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Polycystic kidney disease 2-like 1 (TRPP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
citric acid DM80YI7 Discovery agent N.A. Investigative [10]
flufenamate DMN8AP0 Discovery agent N.A. Investigative [4]
malic acid DMU3O5H Discovery agent N.A. Investigative [10]
phenamil DMJLUFM Discovery agent N.A. Investigative [4]
Drug(s) Targeting Amiloride-sensitive sodium channel (ENaC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Triamterene DM2HU9I Congestive heart failure BD10 Approved [11]
VX-371 DMSTHG1 Cystic fibrosis CA25 Phase 2 [12]
S3969 DM84DMW Discovery agent N.A. Investigative [13]
Drug(s) Targeting Acid-sensing ion channel 3 (ASIC3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
agmatine DMSBZ29 Discovery agent N.A. Investigative [14]
A-317567 DMGWO9J Discovery agent N.A. Investigative [14]
THA-902 DMKCY0X Fibromyalgia MG30.01 Investigative [14]
arcaine DMXOYK0 Discovery agent N.A. Investigative [14]
GMQ DMM0ZKQ Discovery agent N.A. Investigative [14]
APETX2 DM0JW2V Pain MG30-MG3Z Investigative [15]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Transported By Organic cation transporter 1 (SLC22A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [16]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [17]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [18]
Oxaliplatin DMQNWRD Adenocarcinoma 2D40 Approved [19]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [20]
Verapamil DMA7PEW Angina pectoris BA40 Approved [21]
Sorafenib DMS8IFC Adenocarcinoma 2D40 Approved [22]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [23]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [24]
Propranolol DM79NTF Angina pectoris BA40 Approved [25]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Secretin (SCT)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [26]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [27]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Cupric Sulfate DMP0NFQ Fungal infection 1F29-1F2F Approved [29]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [30]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [31]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [32]
Dopamine DMPGUCF Acromegaly 5A60.0 Approved [33]
Pentagastrin DMRCLZB Diagnostic imaging N.A. Approved [34]
CHLORIDE DM1TJXA Solid tumour/cancer 2A00-2F9Z Phase 3 [35]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Diamine oxidase (AOC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [36]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [37]
Amiloride DMRTSGP Congestive heart failure BD10 Approved [38]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [39]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [40]
Methotrexate DM2TEOL Anterior urethra cancer Approved [41]
Aminoguanidine DMJQDUC Diabetic retinopathy 9B71.0 Phase 1 [38]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [42]
PMID28870136-Compound-48 DMPIM9L N. A. N. A. Patented [43]
Putrescine DMWE6V1 Burn and burn infection ND90-NE2Z Discontinued in Phase 2 [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Hepcidin (HAMP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [44]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [45]
Quercetin DM3NC4M Obesity 5B81 Approved [46]
Omeprazole DM471KJ Cystic fibrosis CA25 Approved [47]
Leflunomide DMR8ONJ Arthritis FA20 Approved [48]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [49]
Cantharidin DMBP5N3 Molluscum contagiosum infection 1E76 Approved [7]
Papaverine DMCA9QP Brain ischaemia 8B1Z Approved [7]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Ethanol DMDRQZU Chronic pain MG30 Approved [50]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Sodium/hydrogen exchanger 7 (SLC9A7)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [36]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [51]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [9]
Arsenic DMTL2Y1 N. A. N. A. Approved [52]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [31]
AMG 386 DMQJXL4 Breast cancer 2C60-2C65 Phase 3 [9]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [53]
PMID28870136-Compound-52 DMFDERP N. A. N. A. Patented [54]
Milchsaure DM462BT Pruritus EC90 Investigative [55]
3-iodothyronamine DM3L0F8 Discovery agent N.A. Investigative [56]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Acid-sensing ion channel 3 (ASIC3) TTLGDIS ASIC3_HUMAN Blocker (channel blocker) [2]
Amiloride-sensitive sodium channel (ENaC) TTQM7TE SCNNA_HUMAN; SCNNB_HUMAN; SCNNG_HUMAN; SCNND_HUMAN Blocker (channel blocker) [3]
Polycystic kidney disease 2-like 1 (TRPP2) TTAHD89 PK2L1_HUMAN Blocker (channel blocker) [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [5]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Diamine oxidase (AOC1) OTRC220K AOC1_HUMAN Protein Interaction/Cellular Processes [6]
Hepcidin (HAMP) OT607RBL HEPC_HUMAN Gene/Protein Processing [7]
Secretin (SCT) OTV3MLOO SECR_HUMAN Gene/Protein Processing [8]
Sodium/hydrogen exchanger 7 (SLC9A7) OTVDLTYA SL9A7_HUMAN Gene/Protein Processing [9]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4145).
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 684).
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 742).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 505).
5 Identification of novel substrates and structure-activity relationship of cellular uptake mediated by human organic cation transporters 1 and 2. J Med Chem. 2013 Sep 26;56(18):7232-42.
6 Human kidney amiloride-binding protein: cDNA structure and functional expression. Proc Natl Acad Sci U S A. 1990 Oct;87(19):7347-51. doi: 10.1073/pnas.87.19.7347.
7 A HAMP promoter bioassay system for identifying chemical compounds that modulate hepcidin expression. Exp Hematol. 2015 May;43(5):404-413.e5. doi: 10.1016/j.exphem.2015.01.005. Epub 2015 Jan 26.
8 Activation of transepithelial ion transport by secretin in human intestinal Caco-2 cells. Jpn J Physiol. 2000 Apr;50(2):215-25. doi: 10.2170/jjphysiol.50.215.
9 Molecular cloning and characterization of a novel (Na+,K+)/H+ exchanger localized to the trans-Golgi network. J Biol Chem. 2001 May 18;276(20):17387-94. doi: 10.1074/jbc.M101319200. Epub 2001 Feb 26.
10 Transient receptor potential family members PKD1L3 and PKD2L1 form a candidate sour taste receptor. Proc Natl Acad Sci U S A. 2006 Aug 15;103(33):12569-74.
11 Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis. Cell Physiol Biochem. 2001;11(4):209-18.
12 The in vitro effect of nebulised hypertonic saline on human bronchial epithelium. Eur Respir J. 2018 May 17;51(5):1702652.
13 Small molecule activator of the human epithelial sodium channel. J Biol Chem. 2008 May 2;283(18):11981-94.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 686).
15 Challenges in analgesic drug development. Clin Pharmacol Ther. 2009 Oct;86(4):447-50.
16 Are organic cation transporters capable of transporting prostaglandins? Naunyn Schmiedebergs Arch Pharmacol. 2005 Aug;372(2):125-30.
17 Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther. 2006 Nov;319(2):879-86.
18 Pharmacologic markers and predictors of responses to imatinib therapy in patients with chronic myeloid leukemia. Leuk Lymphoma. 2008 Apr;49(4):639-42.
19 Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 2006 Sep 1;66(17):8847-57.
20 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
21 Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006 Mar 8;234(1):4-33.
22 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
23 Comparison of type I and type II organic cation transport by organic cation transporters and organic anion-transporting polypeptides. J Pharmacol Exp Ther. 2001 Jul;298(1):110-5.
24 Organic cation transporters and their pharmacokinetic and pharmacodynamic consequences. Drug Metab Pharmacokinet. 2008;23(4):243-53.
25 Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145.
26 Retinoic acid-induced human secretin gene expression in neuronal cells is mediated by cyclin-dependent kinase 1. Ann N Y Acad Sci. 2006 Jul;1070:393-8. doi: 10.1196/annals.1317.051.
27 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
28 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
29 Physiological and toxicological transcriptome changes in HepG2 cells exposed to copper. Physiol Genomics. 2009 Aug 7;38(3):386-401.
30 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
31 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
32 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
33 Administration of secretin for autism alters dopamine metabolism in the central nervous system. Brain Dev. 2006 Mar;28(2):99-103. doi: 10.1016/j.braindev.2005.05.005. Epub 2005 Sep 15.
34 Secretin inhibits canine gastric acid secretion in response to pentagastrin by modulating gastric histamine release. J Pharmacol Exp Ther. 1996 Nov;279(2):718-23.
35 The influence of secretin on ion transport in the human jejunum. Gut. 1973 Jun;14(6):485-90. doi: 10.1136/gut.14.6.485.
36 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
37 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
38 Diamine oxidase is the amiloride-binding protein and is inhibited by amiloride analogues. J Biol Chem. 1994 Apr 1;269(13):9921-5.
39 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
40 Comparative Analysis of Transcriptomic Changes including mRNA and microRNA Expression Induced by the Xenoestrogens Zearalenone and Bisphenol A in Human Ovarian Cells. Toxins (Basel). 2023 Feb 9;15(2):140. doi: 10.3390/toxins15020140.
41 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
42 Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. Food Chem Toxicol. 2020 Jun;140:111297. doi: 10.1016/j.fct.2020.111297. Epub 2020 Mar 28.
43 Oxidative stress modulates theophylline effects on steroid responsiveness. Biochem Biophys Res Commun. 2008 Dec 19;377(3):797-802.
44 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
45 Blood cell oxidative stress precedes hemolysis in whole blood-liver slice co-cultures of rat, dog, and human tissues. Toxicol Appl Pharmacol. 2010 May 1;244(3):354-65. doi: 10.1016/j.taap.2010.01.017. Epub 2010 Feb 6.
46 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
47 Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway. Toxicol Lett. 2020 Jan;318:86-91. doi: 10.1016/j.toxlet.2019.10.016. Epub 2019 Oct 24.
48 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
49 Integrative "-Omics" analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 2016 Dec 19;29(12):2164-2174.
50 Alcohol metabolism-mediated oxidative stress down-regulates hepcidin transcription and leads to increased duodenal iron transporter expression. J Biol Chem. 2006 Aug 11;281(32):22974-82. doi: 10.1074/jbc.M602098200. Epub 2006 May 31.
51 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
52 Prenatal arsenic exposure and the epigenome: identifying sites of 5-methylcytosine alterations that predict functional changes in gene expression in newborn cord blood and subsequent birth outcomes. Toxicol Sci. 2015 Jan;143(1):97-106. doi: 10.1093/toxsci/kfu210. Epub 2014 Oct 10.
53 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
54 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
55 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
56 Identification and characterization of 3-iodothyronamine intracellular transport. Endocrinology. 2009 Apr;150(4):1991-9.